Perspectives in Primary Hyperoxaluria - Historical, Current and Future Clinical Interventions

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2021 Dec 9

PMID 34880452

Citations 24

Authors

Kevin Shee

Marshall L Stoller

Affiliations

Soon will be listed here.

Abstract

Primary hyperoxalurias are a devastating family of diseases leading to multisystem oxalate deposition, nephrolithiasis, nephrocalcinosis and end-stage renal disease. Traditional treatment paradigms are limited to conservative management, dialysis and combined transplantation of the kidney and liver, of which the liver is the primary source of oxalate production. However, transplantation is associated with many potential complications, including operative risks, graft rejection, post-transplant organ failure, as well as lifelong immunosuppressive medications and their adverse effects. New therapeutics being developed for primary hyperoxalurias take advantage of biochemical knowledge about oxalate synthesis and metabolism, and seek to specifically target these pathways with the goal of decreasing the accumulation and deposition of oxalate in the body.

Citing Articles

Synthesis and LDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria.

Rico-Molina M, Ortega-Vidal J, Molina-Canteras J, Cobo J, Altarejos J, Salido S Int J Mol Sci. 2025; 25(24.

PMID: 39769031 PMC: 11675970. DOI: 10.3390/ijms252413266.

Identification of a novel GRHPR mutation in primary hyperoxaluria type 2 and establishment of patient-derived iPSC line.

Yan X, Xu Z, Chen Y, Gao L, Jiang Z, Liu L Hum Cell. 2025; 38(2):40.

PMID: 39757298 DOI: 10.1007/s13577-024-01169-5.

Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.

Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S Kidney Int Rep. 2024; 9(11):3083-3096.

PMID: 39534212 PMC: 11551133. DOI: 10.1016/j.ekir.2024.08.031.

A new era in the treatment of kidney diseases: NLRP3 inflammasome and cytokine-targeted therapies.

Leventoglu E, Bakkaloglu S Pediatr Nephrol. 2024; .

PMID: 39485496 DOI: 10.1007/s00467-024-06578-0.

Synthesis of Ethyl Pyrimidine-Quinolincarboxylates Selected from Virtual Screening as Enhanced Lactate Dehydrogenase (LDH) Inhibitors.

Diaz I, Salido S, Nogueras M, Cobo J Int J Mol Sci. 2024; 25(17).

PMID: 39273691 PMC: 11396203. DOI: 10.3390/ijms25179744.

References

Lieske J, Monico C, Holmes W, Bergstralh E, Slezak J, Rohlinger A . International registry for primary hyperoxaluria. Am J Nephrol. 2005; 25(3):290-6. DOI: 10.1159/000086360. View

Hopp K, Cogal A, Bergstralh E, Seide B, Olson J, Meek A . Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J Am Soc Nephrol. 2015; 26(10):2559-70. PMC: 4587693. DOI: 10.1681/ASN.2014070698. View

Asplin J . Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002; 31(4):927-49. DOI: 10.1016/s0889-8529(02)00030-0. View

Mulay S, Kulkarni O, Rupanagudi K, Migliorini A, Darisipudi M, Vilaysane A . Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest. 2012; 123(1):236-46. PMC: 3533282. DOI: 10.1172/JCI63679. View

Holmes R, Assimos D . Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J Urol. 1998; 160(5):1617-24. View

Monico C, Rossetti S, Belostotsky R, Cogal A, Herges R, Seide B . Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011; 6(9):2289-95. PMC: 3358997. DOI: 10.2215/CJN.02760311. View

Giafi C, Rumsby G . Kinetic analysis and tissue distribution of human D-glycerate dehydrogenase/glyoxylate reductase and its relevance to the diagnosis of primary hyperoxaluria type 2. Ann Clin Biochem. 1998; 35 ( Pt 1):104-9. DOI: 10.1177/000456329803500114. View

Booth M, Conners R, Rumsby G, Brady R . Structural basis of substrate specificity in human glyoxylate reductase/hydroxypyruvate reductase. J Mol Biol. 2006; 360(1):178-89. DOI: 10.1016/j.jmb.2006.05.018. View

Belostotsky R, Pitt J, Frishberg Y . Primary hyperoxaluria type III--a model for studying perturbations in glyoxylate metabolism. J Mol Med (Berl). 2012; 90(12):1497-504. DOI: 10.1007/s00109-012-0930-z. View

10.

Cellini B, Bertoldi M, Montioli R, Paiardini A, Borri Voltattorni C . Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications. Biochem J. 2007; 408(1):39-50. PMC: 2049084. DOI: 10.1042/BJ20070637. View

11.

Mdluli K, Booth M, Brady R, Rumsby G . A preliminary account of the properties of recombinant human Glyoxylate reductase (GRHPR), LDHA and LDHB with glyoxylate, and their potential roles in its metabolism. Biochim Biophys Acta. 2005; 1753(2):209-16. DOI: 10.1016/j.bbapap.2005.08.004. View

12.

Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B . Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis. 2018; 47(1):67-78. DOI: 10.1007/s00240-018-1089-z. View

13.

Hoppe B, Beck B, Milliner D . The primary hyperoxalurias. Kidney Int. 2009; 75(12):1264-1271. PMC: 4577278. DOI: 10.1038/ki.2009.32. View

14.

Harambat J, van Stralen K, Espinosa L, Groothoff J, Hulton S, Cerkauskiene R . Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol. 2012; 7(3):458-65. PMC: 3302673. DOI: 10.2215/CJN.07430711. View

15.

Cregeen D, Williams E, Hulton S, Rumsby G . Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat. 2003; 22(6):497. DOI: 10.1002/humu.9200. View

16.

Cramer S, Ferree P, Lin K, Milliner D, Holmes R . The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet. 1999; 8(11):2063-9. DOI: 10.1093/hmg/8.11.2063. View

17.

Milliner D, Wilson D, Smith L . Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. 2001; 59(1):31-6. DOI: 10.1046/j.1523-1755.2001.00462.x. View

18.

Kemper M, Conrad S, Muller-Wiefel D . Primary hyperoxaluria type 2. Eur J Pediatr. 1997; 156(7):509-12. DOI: 10.1007/s004310050649. View

19.

Belostotsky R, Seboun E, Idelson G, Milliner D, Becker-Cohen R, Rinat C . Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010; 87(3):392-9. PMC: 2933339. DOI: 10.1016/j.ajhg.2010.07.023. View

20.

Martin-Higueras C, Garrelfs S, Groothoff J, Jacob D, Moochhala S, Bacchetta J . A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int. 2021; 100(3):621-635. DOI: 10.1016/j.kint.2021.03.031. View